Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies San Antonio, Texas, April 27, 2017 (Newswire.com) – Dr. Fred Poordad, internationally recognized for his research in the field of liver diseases, presented a retreatment study of patients who have failed...
Read MoreSAN ANTONIO, /PRNewswire/ — The Texas Liver Institute announced that Dr. Naim Alkhouri has joined the staff as their Director of the Metabolic Center and will have a leadership role in the Pediatric Liver Disease Program at University Hospital and UT Health. Dr. Alkhouri is well-known globally for his expertise...
Read MoreBy Ray Cavanaugh Ray Cavanaugh is a freelance writer from Boston, MA. His interests include history, health topics, and current events in faraway places. They have fatty liver disease, but they aren’t alcoholic, nor are they adults. In the US alone, about seven million children – many of them...
Read MoreFatty liver is a condition where the liver becomes infiltrated with fat. Most people with fatty liver are overweight, have diabetes or pre-diabetes.
Read MoreSAN ANTONIO — Fatty liver disease can be caused by drinking too much, but in many men genetics and diet can trigger the illness. “There are a lot of untapped mysteries in the liver that we are discovering every day,” said Dr. Fred Poordad, Chief of Hepatology at the...
Read MoreJust a few years ago the outlook for treating patients with chronic hepatitis C was grim. For almost a year, patients would receive a complicated regimen of shots and up to 18 pills a day with drugs that caused major side effects. After that, there was a six-month follow-up...
Read MoreWatch the Dr. Phil interview with Dr. Poordad
Read MoreBARCELONA — Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a pangenotypic NS5A inhibitor, produced sustained virologic response rates around 90% in a cohort of treatment-experienced patients, including those with resistance-associated variants, according to findings presented at the International Liver Congress. Fred Poordad, MD, of The...
Read MoreBARCELONA — An investigational drug combination offers renewed hope of a cure for chronic hepatitis C (HCV) patients who have tried and failed therapy with the new direct-acting antiviral agents, a researcher said here. Cure rates with the new agents — sofosbuvir (Sovaldi), combined with velpatasvir and GS-9857 —...
Read MoreBARCELONA — A new three-pronged approach to hepatitis C virus effectively treated prior non-responders with genotype 1, according to a presenter at the International Liver Congress. “As increasing numbers of patients get treated, the number of patients that, cumulatively, will fail will increase over time despite rates of 95%...
Read More